Eledon Pharmaceuticals, Inc. ((ELDN)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eledon Pharmaceuticals, Inc. is conducting a Phase 2 clinical study titled ‘AT-1501-K209: BESTOW-EXTENSION’ to assess the long-term safety and efficacy of Tegoprubart in kidney transplant recipients. The study aims to provide insights into the potential benefits of Tegoprubart over the commonly used drug Tacrolimus, focusing on preventing kidney transplant rejection.
The study tests two interventions: Tegoprubart (AT-1501) and Tacrolimus. Tegoprubart is administered intravenously every three weeks, while Tacrolimus is given orally with dosage adjustments to maintain specific blood levels. Both treatments are combined with other standard medications like MMF or MPS and corticosteroids.
This interventional study is non-randomized with a parallel assignment model, meaning participants are assigned to one of the two treatment groups. There is no masking involved, allowing both participants and researchers to know which treatment is being administered. The primary goal is treatment-focused.
The study began on November 6, 2023, with the latest update submitted on July 21, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results, which can impact market and investor decisions.
The update on this study could influence Eledon Pharmaceuticals’ stock performance, as positive outcomes may enhance investor confidence and position the company favorably against competitors in the kidney transplant treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.